Articles

New information about kataegis offers hope

Genetic phenomenon proves to be a positive marker in breast cancer
Written byRachel Flehinger
| 3 min read

SAN DIEGO—Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have recently discovered that an anomaly present in some cancers is in fact a marker for a good prognosis in breast cancer. Kataegis, named for the ancient Greek word for thunder, refers to instances where multiple mutations cluster in various spots within a genome. Detailed analysis of human tumor genetic data in breast cancer has shown that patients with such “mutation hotspots” have less-invasive tumors and better prognoses.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.